

LES CENT Gardes



Cent Gardes Conference: HIV Vaccines

In memory of Dr. Charles Mérieux

Organized by Fondation Mérieux

"Les Pensières"

Fondation Mérieux Conference Center

Veyrier du Lac - France

October 25 to 27, 2015



des racines pour la vie • roots for life



Steering Committee

Members	Institutions
Françoise Barré-Sinoussi	Institut Pasteur France
Jean-François Delfraissy	Agence Nationale de Recherche sur le Sida (ANRS) INSERM AVIESAN France
Marc P Girard	Académie Nationale de Médecine France
Roger Le-Grand	CEA/INSERM/Université Paris Sud France
Yves Levy	VRI / INSERM France
Benoît Miribel	Fondation Mérieux France

Scientific Advisory Board

Members	Institutions
Galit Alter	Ragon Institute UK
Francis Barin	Université François-Rabelais & INSERM U966 France
Zhiwei Chen	AIDS Institute, The University of Hong Kong China
Marc P Girard	Académie Nationale de Médecine France
Roger Le-Grand	CEA/INSERM/Université Paris Sud France
Lynn Morris	National Institute for Communicable Diseases South Africa
Louis Picker	Oregon Health & Science University Vaccine and Gene Therapy Institute USA
Pascal Poignard	IAVI / TSRI USA
Sahra Rowland-Jones	Nuffield Department of Medicine, Oxford University UK
Gabriella Scarlatti	San Raffaele Scientific Institute Italia
Hanneke Schuitemaker	Janssen The Netherlands
Barbara Shacklett	University of California at Davis USA

Organizing Committee

Members	Institutions
Marc P Girard	Académie Nationale de Médecine France
Cindy Grasso	Fondation Mérieux France
Christophe Longuet	Fondation Mérieux France
Valentina Picot	Fondation Mérieux France

Scientific Programme

Sunday, October 25th 2015

Introduction

Chairs: Mary Marovitch and Jean François Delfraissy

12h30	Registration	
14h00-14h30	Welcome addresses	<ul style="list-style-type: none"> • Benoît Miribel • Jean-François Delfraissy • Marc Girard
14h30-15h15	The B Cell Pathway	Barton Haynes
15h15-16h00	The T cell pathway	Bruce Walker
16h00-16h45	<i>Coffee Break</i>	

Session 1

Blocking Virus Entry

Chairs: Lynn Morris and Robin Shattock

16h45-17h30	Impact of HIV phenotype on transmission and disease progression	Eric Hunter
17h30-17h50	Type I Interferons: Barriers or Pathways to Virus Entry?	Netanya Sandler-Utay
17h50-18h10	Induction of HIV-1 broadly neutralizing antibodies: The role of host and viral determinants	Alexandra Trkola
18h10-18h30	Untitled abstract	Michael Farzan
18h30-18h50	The role of immune activation and the microbiome in mucosal transmission of SIV	Jay A. Berzofsky
18h50-19h10	Inactivated AT-2 treated SIVmac239 and Lactobacillus plantarum (LP) as a candidate AIDS vaccine	Guido Silvestri
19h10-19h45	<i>General discussion</i>	
19h45	Welcome Reception and Diner	

Monday, October 26th 2015

Session 2

Broadly Neutralizing Antibodies

Chair: Hanneke Schuitemaker and Wayne Koff

8h00-8h45	Broadly neutralizing antibodies to HIV	Dennis Burton
8h45-9h05	Reproducible antibody lineages as templates for vaccine design	Peter Kwong
9h05-9h25	Broadly neutralizing antibody 8ANC195 recognizes closed and open conformational states of HIV-1 Env	Pamela Bjorkman
9h25-9h45	Antiviral Properties of Broadly Neutralizing HIV-1 Antibodies	Hugo Mouquet
9h45-10h00	General Discussion	
10h00-10h45	<i>Coffee Break</i>	

Session 3

Passive Immunization and VIP

Chair: Sarah Rowland-Jones and Pascal Poignard

10h45-11h30	Overview of HIV Antibodies for Prevention and Treatment	John Mascola
11h30-11h50	Passive Immunization for Prevention and Treatment of HIV	Barney Graham
11h50-12h10	Immunotherapy for HIV-1 in Humans	Michel Nussenzweig
12h10-12h30	Ability to Develop Broadly Neutralizing HIV-1 Antibodies is not Restricted by the Germline Immunoglobulin Gene Repertoire	Lynn Morris
12h30-12h40	Abstract not provided	Gary Nabel
12h40-13h00	General Discussion	
13h00	Lunch	

Session 4**Antibody Effector Functions**

Chair: Francis Barin and Christiane Moog

14h00-14h45	Introduction	Galit Alter
14h45-15h05	Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control	Margie Ackerman
15h05-15h25	ADCC antibodies and the prevention of HIV acquisition	Stephen Kent
15h25-15h45	Novel SHIV Design to Elicit Broadly Neutralizing Antibodies and Guide Iterative Vaccine Development	George Shaw
15h45-16h00	General Discussion	
16h00-16h45	<i>Coffee Break</i>	

Session 5**Mucosal Immune Responses**

Chair: Mario Clerici and Elizabeth Menu

16h45-17h30	Prevention of HIV Infection at Mucosal Sites of HIV Exposure	Julie Mc Elrath
17h30-17h50	Characterizing antibodies from new populations	Julie Overbaugh
17h50-18h10	Mucosal IgA: Protection Against SHIV Infection by Passive and Active Immunization	Ruth Ruprecht
18h10-18h30	Natural control of HIV-1 infection in the uterine mucosa: a model for developing novel protective vaccine strategies?	Elizabeth Menu
18h30-18h50	The in vivo effects of anti- $\alpha 4\beta 7$ in rhesus macaques during acute and chronic infection	James Arthos
18h50-19h10	Mechanisms of HIV-1 restriction and dissemination mediated by intestinal mucosal myeloid cells	Gabriella Scarlatti
19h10-19h30	Abstract not provided	Jo-Ann Passmore
19h30-20h00	<i>General Discussion</i>	
20h00	Diner	

Tuesday, October 27th 2015

Session 6

Cellular Immune Responses

Chair: Barbara Shacklett and Louis Picker

8h00-8h45	Cytomegalovirus Vectors: Exceptional Efficacy from Unconventional Cellular Immune Responses	Louis Picker
8h45-9h05	T follicular helper cells are the major source of replication and infectious HIV in long-term ART treated subjects	Giuseppe Pantaleo
9h05-9h25	Peripheral T follicular helper cells responses in HIV vaccine trials	Hendrik Streeck
9h25-9h45	Relationship between CD4+ T cell subsets and the neutralisation breadth of the antibody response generated during HIV-1 infection	Persephone Borrow
9h45-10h05	From mechanism of action of MVA-HIV vaccine candidate to clinical trial	Olivier Schwartz
10h05-10h25	General Discussion	
10h25-11h00	<i>Coffee Break</i>	

Session 7

Update on Clinical trials

Chair: Galit Alter and Zhiwei Chen

11h00-11h45	HIV vaccines trials: Advancing into Efficacy	Glenda Gray
11h45-12h05	Update on clinical trials	Jerome Kim
12h05-12h25	Preclinical-to-Clinical HIV Vaccine Development	Dan Barouch
12h25-12h45	HIV-1 Vaccine Humoral Immunity, Immune Correlates and Mechanistic Insights	Georgia Tomaras
12h45-13h00	General Discussion	
13h00	Lunch	

Session 8**Control of Virus reservoirs**

Chair: Olivier Lambotte and Michaela Muller Trutwin

14h15-15h00	Identifying The HIV Reservoir	Danny Douek
15h00-15h20	Persistent Inflammation during ART and its Potential Impact on Therapeutic Vaccines	Steven Deeks
15h20-15h40	Abstract not provided	Monsef Benkirane
15h40-16h00	Treatment with a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys	James Whitney
16h00-16h15	General Discussion	

Session 9**Prospects and Conclusions**

Chair: Patrice Debré and Gabriella Scarlatti

16h15-16h35	Protection from heterologous SHIV infection by vaccination with a replication-competent VSV-HIV Env vaccine	Wayne Koff
16h35-17h00	Towards an HIV Cure: HIV remission as a first step	Asier Saez-Cirion
17h00-17h30	Conclusions	Françoise Barré-Sinoussi
17h30	End of Meeting	